https://www.selleckchem.com/pr....oducts/cdk2-inhibito
We estimate that there were very large increases in the percentage of patients diagnosed at stages I or II between 2008-09 and 2012-13 from 32% to 44% for colorectal cancer, 19% to 25% for non-small cell lung cancer, and 28% to 31% for ovarian cancer. Geographical inequalities reduced for colorectal and ovarian cancer. Interpretation Multiple imputation is an optimal approach to reduce bias from missing data, but residual bias may be present in these estimates. Increases in early-stage diagnosis coincided with increased diagno
Like
Comment
Share
